Literature DB >> 27008037

A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.

Walter Ling1.   

Abstract

Four decades of concerted pharmacotherapy research has netted us three medications approved for the treatment of opioid addiction. The clinical pharmacology, safety, efficacy, and clinical use of these medications are familiar to most clinical researchers and clinicians in addiction medicine. Less common is an understanding of the social and political forces behind the choice of these particular agents for their development and how these forces continue to influence how clinicians interact with patients who have opioid use disorder. This review brings into focus those forces and puts into context how we came to have these particular medications. What we know determines our views of the world we live in, including our patients and ourselves, as well as those to whom we give power to govern us. The issues are raised by the author, who does not provide resolutions; answers to the questions of how to address the issues must come from the reader.

Entities:  

Keywords:  Buprenorphine; Methadone; Naltrexone; Opioids; Pharmacotherapy

Mesh:

Substances:

Year:  2016        PMID: 27008037     DOI: 10.1007/s11481-016-9663-z

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  21 in total

1.  Datapoints: Trends in naltrexone use among members of a large private health plan.

Authors:  Katherine M Harris; Andrea DeVries; Kelli Dimidjian
Journal:  Psychiatr Serv       Date:  2004-03       Impact factor: 3.084

Review 2.  A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence.

Authors:  Hendrik G Roozen; Ranne de Waart; Danielle A W M van der Windt; Wim van den Brink; Cor A J de Jong; Ad J F M Kerkhof
Journal:  Eur Neuropsychopharmacol       Date:  2005-12-19       Impact factor: 4.600

3.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

Review 4.  Antagonist Models for Relapse Prevention and Reducing HIV Risk.

Authors:  George E Woody; Evgeny Krupitsky; Edwin Zvartau
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-27       Impact factor: 4.147

5.  Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study.

Authors:  M Gossop; J Marsden; D Stewart; S Treacy
Journal:  Drug Alcohol Depend       Date:  2001-05-01       Impact factor: 4.492

6.  A meta-analysis comparing the effectiveness of buprenorphine and methadone.

Authors:  S L West; K K O'Neal; C W Graham
Journal:  J Subst Abuse       Date:  2000

7.  Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Authors:  S L Walsh; K L Preston; G E Bigelow; M L Stitzer
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

8.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

Authors:  V P DOLE; M NYSWANDER
Journal:  JAMA       Date:  1965-08-23       Impact factor: 56.272

Review 9.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

10.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis.

Authors:  Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell
Journal:  Drug Alcohol Depend       Date:  2003-09-10       Impact factor: 4.492

View more
  4 in total

1.  Promoting Global Health - Prevention and Treatment of Substance Abuse and HIV in Asia.

Authors:  Ming D Li; Yih-Ing Hser; Zhiwei Chen; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

2.  Hypothesizing that a Pro-Dopaminergic Regulator (KB220z Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.

Authors:  Kenneth Blum; Debra Whitney; Lye Fried; Marcelo Febo; Roger L Waite; Eric R Braverman; Kristina Dushaj; Mona Li; John Giordano; Zsolt Demetrovics; Rajendra D Badgaiyan
Journal:  Clin Med Rev Case Rep       Date:  2016-08-16

Review 3.  Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.

Authors:  Walter Ling; Steve Shoptaw; David Goodman-Meza
Journal:  Subst Abuse Rehabil       Date:  2019-11-29

4.  French-Canadian Translation and Cultural Adaptation of the Clinical Opiate Withdrawal Scale: The COWS-FC.

Authors:  Alice Bruneau; Clarice Poirier; Mélanie Bérubé; Aline Boulanger; Céline Gélinas; Line Guénette; Anaïs Lacasse; David Lussier; Yannick Tousignant-Laflamme; M Gabrielle Pagé; Marc O Martel
Journal:  Can J Psychiatry       Date:  2022-03-15       Impact factor: 5.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.